WO2003008409A1 - Quinoline derivatives and their use as tyrosine kinase inhibitors - Google Patents
Quinoline derivatives and their use as tyrosine kinase inhibitors Download PDFInfo
- Publication number
- WO2003008409A1 WO2003008409A1 PCT/GB2002/003177 GB0203177W WO03008409A1 WO 2003008409 A1 WO2003008409 A1 WO 2003008409A1 GB 0203177 W GB0203177 W GB 0203177W WO 03008409 A1 WO03008409 A1 WO 03008409A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- group
- formula
- pyrrolidin
- piperidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003513968A JP4326328B2 (ja) | 2001-07-16 | 2002-07-10 | キノリン誘導体及びそれらのチロシンキナーゼ阻害薬としての使用 |
EP02745602A EP1409481B1 (en) | 2001-07-16 | 2002-07-10 | Quinoline derivatives and their use as tyrosine kinase inhibitors |
DE60215178T DE60215178T2 (de) | 2001-07-16 | 2002-07-10 | Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase |
US10/483,782 US7501516B2 (en) | 2001-07-16 | 2002-07-10 | Quinoline derivatives and their use as tyrosine kinase inhibitors |
HK04106001A HK1063185A1 (en) | 2001-07-16 | 2004-08-10 | Quinoline derivatives and their use as tyrosine kinase inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01401895 | 2001-07-16 | ||
EP01401895.6 | 2001-07-16 | ||
EP01403123 | 2001-12-05 | ||
EP01403123.1 | 2001-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003008409A1 true WO2003008409A1 (en) | 2003-01-30 |
Family
ID=26077248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2002/003177 WO2003008409A1 (en) | 2001-07-16 | 2002-07-10 | Quinoline derivatives and their use as tyrosine kinase inhibitors |
Country Status (8)
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003047584A1 (en) * | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Quinoline derivatives |
WO2003093241A1 (en) * | 2002-04-30 | 2003-11-13 | Wyeth Holdings Corporation | Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles |
WO2004005284A1 (en) * | 2002-07-09 | 2004-01-15 | Astrazeneca Ab | Substituted 3-cyanoquinolines as mek inhibitors |
WO2004069250A1 (en) * | 2003-02-03 | 2004-08-19 | Astrazeneca Ab | 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors |
WO2004069249A1 (en) * | 2003-02-03 | 2004-08-19 | Astrazeneca Ab | 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors |
US6849625B2 (en) | 2000-10-13 | 2005-02-01 | Astrazeneca Ab | Quinazoline derivatives with anti-tumour activity |
US6939866B2 (en) | 2000-10-13 | 2005-09-06 | Astrazeneca Ab | Quinazoline derivatives |
US7115615B2 (en) | 2000-08-21 | 2006-10-03 | Astrazeneca | Quinazoline derivatives |
US7141577B2 (en) | 2001-04-19 | 2006-11-28 | Astrazeneca Ab | Quinazoline derivatives |
JP2007501210A (ja) * | 2003-08-06 | 2007-01-25 | アストラゼネカ アクチボラグ | 血管新生阻害剤としてのキナゾリン誘導体 |
US7173136B2 (en) | 2002-11-02 | 2007-02-06 | Astrazeneca Ab | 3-Cyano-quinoline derivatives |
US7402583B2 (en) | 2000-11-02 | 2008-07-22 | Astrzenca Ab | Substituted quinolines as antitumor agents |
US7462623B2 (en) | 2002-11-04 | 2008-12-09 | Astrazeneca Ab | Quinazoline derivatives as Src tyrosine kinase inhibitors |
US7504408B2 (en) | 2002-07-09 | 2009-03-17 | Astrazeneca Ab | Quinzoline derivatives for use in the treatment of cancer |
US7842701B2 (en) | 2004-02-19 | 2010-11-30 | Takeda Pharmaceutical Company Limited | Pyrazoloquinolone derivative and use thereof |
US7884114B2 (en) | 2007-08-15 | 2011-02-08 | Glaxo Group Limited | Compounds |
WO2016016894A1 (en) | 2014-07-30 | 2016-02-04 | Yeda Research And Development Co. Ltd. | Media for culturing pluripotent stem cells |
WO2020152686A1 (en) | 2019-01-23 | 2020-07-30 | Yeda Research And Development Co. Ltd. | Culture media for pluripotent stem cells |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA06007017A (es) | 2003-12-18 | 2006-08-31 | Janssen Pharmaceutica Nv | Derivados de pirido y pirimidopirimidina como agentes antiproliferativos. |
JO3088B1 (ar) * | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
WO2008006884A2 (en) * | 2006-07-13 | 2008-01-17 | Janssen Pharmaceutica N.V. | Mtki quinazoline derivatives |
WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
WO2011153942A1 (zh) * | 2010-06-09 | 2011-12-15 | 天津和美生物技术有限公司 | 氰基喹啉衍生物 |
AU2016333987A1 (en) | 2015-10-05 | 2018-05-10 | Ny State Psychiatric Institute | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies |
CN112040952B (zh) * | 2018-02-20 | 2023-03-31 | 苏州韬略生物科技股份有限公司 | 用作激酶抑制剂的取代的喹啉 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998043960A1 (en) * | 1997-04-03 | 1998-10-08 | American Cyanamid Company | Substituted 3-cyano quinolines |
WO2000018761A1 (en) * | 1998-09-29 | 2000-04-06 | American Cyanamid Company | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
WO1995024190A2 (en) * | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
CA2252501A1 (en) | 1996-05-20 | 1997-11-27 | Darwin Discovery Limited | Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors |
SK283162B6 (sk) | 1996-05-20 | 2003-03-04 | Darwin Discovery Limited | Karboxamid chinolínu ako inhibítor faktora nekrotizujúceho nádor, inhibítor fosfodiesterázy-IV a farmaceutický prostriedok s jeho obsahom |
JP2001500890A (ja) | 1996-09-25 | 2001-01-23 | ゼネカ リミテッド | Vegfのような成長因子の作用を阻害するキノリン誘導体 |
GB9712761D0 (en) | 1997-06-17 | 1997-08-20 | Chiroscience Ltd | Quinolines and their therapeutic use |
DE69723863T2 (de) | 1996-11-06 | 2004-04-15 | Darwin Discovery Ltd., Slough | Chinoline und deren therapeutische verwendung |
US6288082B1 (en) * | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
KR20080015482A (ko) * | 1999-02-10 | 2008-02-19 | 아스트라제네카 아베 | 혈관형성 억제제로서의 퀴나졸린 유도체 |
GB9904103D0 (en) | 1999-02-24 | 1999-04-14 | Zeneca Ltd | Quinoline derivatives |
GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
KR20020018201A (ko) | 1999-08-12 | 2002-03-07 | 윌리암 에이취 캘넌, 에곤 이 버그 | 결장 폴립 및 결장직장암의 치료 또는 억제용엔에스에이아이디 및 이지에프알 키나제 억제제 함유 조성물 |
WO2001055116A2 (en) | 2000-01-28 | 2001-08-02 | Astrazeneca Ab | Quinoline derivatives and their use as aurora 2 kinase inhibitors |
AR035851A1 (es) | 2000-03-28 | 2004-07-21 | Wyeth Corp | 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
KR20080027400A (ko) | 2000-08-21 | 2008-03-26 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
AU2001292137A1 (en) | 2000-10-13 | 2002-04-22 | Astrazeneca Ab | Quinazoline derivatives |
EP1326859A1 (en) | 2000-10-13 | 2003-07-16 | AstraZeneca AB | Quinazoline derivatives with anti-tumour activity |
JP2004512335A (ja) | 2000-10-25 | 2004-04-22 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
JP2004517059A (ja) | 2000-11-02 | 2004-06-10 | アストラゼネカ アクチボラグ | 抗腫瘍剤用の4−置換キノリン類 |
WO2002044166A1 (en) | 2000-11-02 | 2002-06-06 | Astrazeneca Ab | Substituted quinolines as antitumor agents |
JP4307843B2 (ja) | 2001-04-19 | 2009-08-05 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
US6713462B2 (en) | 2001-06-21 | 2004-03-30 | Ariad Pharmaceuticals, Inc. | Quinolinones and uses thereof |
GB0129099D0 (en) | 2001-12-05 | 2002-01-23 | Astrazeneca Ab | Chemical compounds |
AU2002347336A1 (en) | 2001-12-05 | 2003-06-17 | Astrazeneca Ab | Quinoline derivatives |
WO2003047584A1 (en) | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Quinoline derivatives |
GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
-
2002
- 2002-07-10 JP JP2003513968A patent/JP4326328B2/ja not_active Expired - Fee Related
- 2002-07-10 ES ES02745602T patent/ES2272737T3/es not_active Expired - Lifetime
- 2002-07-10 DE DE60215178T patent/DE60215178T2/de not_active Expired - Lifetime
- 2002-07-10 US US10/483,782 patent/US7501516B2/en not_active Expired - Fee Related
- 2002-07-10 WO PCT/GB2002/003177 patent/WO2003008409A1/en active IP Right Grant
- 2002-07-10 EP EP02745602A patent/EP1409481B1/en not_active Expired - Lifetime
- 2002-07-10 AT AT02745602T patent/ATE341545T1/de not_active IP Right Cessation
-
2004
- 2004-08-10 HK HK04106001A patent/HK1063185A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998043960A1 (en) * | 1997-04-03 | 1998-10-08 | American Cyanamid Company | Substituted 3-cyano quinolines |
WO2000018761A1 (en) * | 1998-09-29 | 2000-04-06 | American Cyanamid Company | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
Non-Patent Citations (2)
Title |
---|
D. H. BOSCHELLI ET. AL.: "Synthesis and Src Kinase Inhibitory Activity of a Series of 4-Phenylamino-3-quinolinecarbonitriles.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, no. 5, 2001, pages 822 - 33, XP001105607 * |
Y. D. WANG ET. AL.: "Inhibitors of Src Tyrosine Kinase: The Preparation and Structure-Activity Relationship of 4-Anilino-3-cyanoquinolines and 4-Anilinoquinazolines.", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 10, 2000, pages 2477 - 80, XP004224243 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115615B2 (en) | 2000-08-21 | 2006-10-03 | Astrazeneca | Quinazoline derivatives |
US6849625B2 (en) | 2000-10-13 | 2005-02-01 | Astrazeneca Ab | Quinazoline derivatives with anti-tumour activity |
US6939866B2 (en) | 2000-10-13 | 2005-09-06 | Astrazeneca Ab | Quinazoline derivatives |
US7402583B2 (en) | 2000-11-02 | 2008-07-22 | Astrzenca Ab | Substituted quinolines as antitumor agents |
US7141577B2 (en) | 2001-04-19 | 2006-11-28 | Astrazeneca Ab | Quinazoline derivatives |
WO2003047584A1 (en) * | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Quinoline derivatives |
WO2003093241A1 (en) * | 2002-04-30 | 2003-11-13 | Wyeth Holdings Corporation | Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles |
AU2003231162B2 (en) * | 2002-04-30 | 2009-08-06 | Wyeth Holdings Corporation | Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles |
US6780996B2 (en) | 2002-04-30 | 2004-08-24 | Wyeth Holdings Corporation | Process for the preparation of 7-substituted-3 quinolinecarbonitriles |
US7504408B2 (en) | 2002-07-09 | 2009-03-17 | Astrazeneca Ab | Quinzoline derivatives for use in the treatment of cancer |
US7173135B2 (en) | 2002-07-09 | 2007-02-06 | Astrazeneca Ab | Substituted 3-cyanoquinolines as MEK inhibitors |
WO2004005284A1 (en) * | 2002-07-09 | 2004-01-15 | Astrazeneca Ab | Substituted 3-cyanoquinolines as mek inhibitors |
US7173136B2 (en) | 2002-11-02 | 2007-02-06 | Astrazeneca Ab | 3-Cyano-quinoline derivatives |
US7462623B2 (en) | 2002-11-04 | 2008-12-09 | Astrazeneca Ab | Quinazoline derivatives as Src tyrosine kinase inhibitors |
WO2004069249A1 (en) * | 2003-02-03 | 2004-08-19 | Astrazeneca Ab | 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors |
WO2004069250A1 (en) * | 2003-02-03 | 2004-08-19 | Astrazeneca Ab | 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors |
JP2007501210A (ja) * | 2003-08-06 | 2007-01-25 | アストラゼネカ アクチボラグ | 血管新生阻害剤としてのキナゾリン誘導体 |
JP4890249B2 (ja) * | 2003-08-06 | 2012-03-07 | アストラゼネカ アクチボラグ | 血管新生阻害剤としてのキナゾリン誘導体 |
US7842701B2 (en) | 2004-02-19 | 2010-11-30 | Takeda Pharmaceutical Company Limited | Pyrazoloquinolone derivative and use thereof |
US7884114B2 (en) | 2007-08-15 | 2011-02-08 | Glaxo Group Limited | Compounds |
WO2016016894A1 (en) | 2014-07-30 | 2016-02-04 | Yeda Research And Development Co. Ltd. | Media for culturing pluripotent stem cells |
WO2020152686A1 (en) | 2019-01-23 | 2020-07-30 | Yeda Research And Development Co. Ltd. | Culture media for pluripotent stem cells |
Also Published As
Publication number | Publication date |
---|---|
US20050009867A1 (en) | 2005-01-13 |
EP1409481B1 (en) | 2006-10-04 |
DE60215178D1 (de) | 2006-11-16 |
DE60215178T2 (de) | 2007-08-23 |
JP2004536860A (ja) | 2004-12-09 |
US7501516B2 (en) | 2009-03-10 |
ES2272737T3 (es) | 2007-05-01 |
ATE341545T1 (de) | 2006-10-15 |
EP1409481A1 (en) | 2004-04-21 |
JP4326328B2 (ja) | 2009-09-02 |
HK1063185A1 (en) | 2004-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2419301C (en) | Quinazoline derivatives | |
EP1292594B1 (en) | Quinazoline derivatives for the treatment of tumours | |
US7501516B2 (en) | Quinoline derivatives and their use as tyrosine kinase inhibitors | |
US6849625B2 (en) | Quinazoline derivatives with anti-tumour activity | |
US20060089382A1 (en) | Substituted 3-cyanoquinolines as mek inhibitors | |
EP1381599B1 (en) | Quinazoline derivatives | |
AU2001278609A1 (en) | Quinazoline derivatives | |
US20040063733A1 (en) | Quinazoline derivatives | |
US20070191346A1 (en) | 3-Cyano-quinoline derivatives | |
WO2002092578A1 (en) | Quinazoline derivatives | |
US6939866B2 (en) | Quinazoline derivatives | |
WO2003048159A1 (en) | Quinoline derivatives | |
WO2003047584A1 (en) | Quinoline derivatives | |
WO2004108704A1 (en) | Pyrimidin-4-yl 3-cyanoquinoline derivatives for use in the treatment of tumours | |
WO2004069250A1 (en) | 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors | |
WO2004108703A1 (en) | Pyrazinyl 3-cyanoquinoline derivatives for use in the treatment of tumours | |
WO2004069249A1 (en) | 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors | |
WO2004069827A1 (en) | Quinoline derivatives and use thereof as antitumor agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003513968 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002745602 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002745602 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10483782 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002745602 Country of ref document: EP |